Neu­ro­Vive shares crater on PhII flop; F-Prime con­tributes $7.5M in start­up cash for Akriveia

Shares of Neu­ro­Vive Phar­ma­ceu­ti­cals tanked Thurs­day af­ter the small Swedish biotech re­port­ed that it is scrap­ping its cy­closporine for­mu­la­tion in acute kid­ney in­jury af­ter watch­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER